OPK · CIK 0000944809
What OPKO Health, Inc. told the SEC could break it.
OPKO's disclosures split between its diagnostics and pharmaceutical sides. Diagnostics — its largest segment — depends on complex Medicare, Medicaid, and third-party billing and reimbursement, where ambiguous rules and potential retroactive adjustments create estimation and collectability risk on the revenue it recognizes. Its pharmaceutical operations span eight countries, with manufacturing at sites in Ireland, Mexico, and Spain plus reliance on third-party CDMOs for clinical supply, so disruption at any of them could impair supply — and its Ireland unit (EirGen, Rayaldee) and related goodwill are flagged as exposed to changing global trade policy and new tariffs. Underlying both is financial pressure: a $117.4 million loss from operations in 2025, a need for additional funds, and 2029 convertible notes.
4 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Geographic concentration
- international pharma operations (8 countries); Ireland (EirGen/Rayaldee) tariff/goodwill exposuremedium
OPKO's pharmaceutical segment operates across Chile, Mexico, Ireland, Israel, Spain, Ecuador, France and the U.S.; its Ireland reporting unit (EirGen Pharma, Rayaldee) and related goodwill (~$163M diagnostics segment goodwill noted) could be impaired by changing global trade policies and new tariffs.
“particularly for our Ireland reporting unit (which includes our wholly owned subsidiary, EirGen Pharma Ltd. 49 Table of Contents ("EirGen") and Rayaldee ), could be impacted by changing global trade policies and the imposition of new tariffs.”
SEC filing →As of 2026
Regulatory & policy
- diagnostics revenue exposed to Medicare/Medicaid reimbursement complexity and retroactive adjustmentsmedium
OPKO's diagnostics revenue (its largest segment) depends on complex third-party, Medicare and Medicaid billing/reimbursement; ambiguous reimbursement regulations, claims-processing and potential retroactive adjustments create estimation and collectability risk for recognized revenue.
“Estimated collection amounts are subject to the complexities and ambiguities of billing, reimbursement regulations and claims processing, as well as considerations unique to Medicare and Medicaid programs, and require us to consider the potential for retroactive adjustments when”
SEC filing →As of 2026
Supplier concentration
- pharmaceutical manufacturing at three sites plus reliance on third-party CDMOs for clinical supplymedium
OPKO manufactures pharmaceuticals at facilities in Waterford (Ireland), Guadalajara (Mexico) and Banyoles (Spain) and relies on various third parties for formulation and manufacture of clinical supplies; disruption at these sites or CDMOs could impair supply of its products and candidates.
“Our current pharmaceutical manufacturing facilities are located in Waterford, Ireland, Guadalajara, Mexico, and Banyoles, Spain. In addition to such facilities, we have entered into agreements with various third parties for the formulation and manufacture of our pharmaceutical clinical supplies.”
SEC filing →As of 2026
Liquidity & debt
- continued operating losses ($117.4M in 2025); need for additional funds; 2029 convertible noteslow
OPKO posted a $117.4M consolidated loss from operations in 2025 and will need additional funds to advance product development, acquisitions or new clinical trials; it carries 2029 Convertible Notes, leaving it dependent on operating cash flow and capital-market access.
“If we acquire additional assets or companies, accelerate our product development programs or initiate additional clinical trials, we will need additional funds.”
SEC filing →As of 2026
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings, including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its customers
“In connection with the Entera Collaboration Agreement, the Company purchased 3,685,226 ordinary shares of Entera at a price of $ 2.17 per share, for an aggregate purchase price of approximately $ 8.0 million. Entera has agreed to utilize the proceeds from this share purchase to fund its 40 % share of the program's development costs through the completion of Phase 1.”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch